HX GROUP(SH:600851) Quan Jing Wang·2025-09-19 10:22Group 1 - The core viewpoint of the article highlights the recent developments in HaiXin Co., Ltd.'s pharmaceutical sector, particularly in the area of oncology drug research and development [1] - The chairman of HaiXin Co., Ltd., Deng Haibin, stated that the company's pharmaceutical subsidiaries are primarily traditional generic drug companies, focusing on post-marketing clinical trial evaluations of existing key products and promoting the consistency evaluation of generic drugs [1] - Regarding the clinical trial progress of HaiXin Biotech's APDC, it was mentioned that the design of the Phase III clinical trial was established a long time ago, leading to difficulties in patient enrollment, and the company is currently exploring solutions to this issue [1]